The Gemini Report – Investment Deep Dives

Comprehensive Equity Analysis: Tecan Group Ltd. (TECN.SW)

All investment deep dives on this site have been written by Google Gemini with light human editing. Nothing on this site constitutes investment advise. All materials on this site are for informational purposes only.

The Gemini Report - Investment Deep Dives
The Gemini Report – Investment Deep Dives
Comprehensive Equity Analysis: Tecan Group Ltd. (TECN.SW)
Loading
/

Executive Summary

This report provides a comprehensive analysis of Tecan Group Ltd. (Tecan), a leading Swiss-based global provider of laboratory automation instruments and solutions. The analysis indicates that Tecan is strategically positioned at the intersection of several enduring secular growth trends, including rising pharmaceutical R&D spending, the expansion of the biotechnology and personalized medicine sectors, and the increasing demand for laboratory automation.

The company operates a highly synergistic dual-business model, comprising a Life Sciences Business (end-customer) and a Partnering Business (OEM). This structure creates a powerful feedback loop, de-risking innovation and fostering deep, high-switching-cost relationships with customers. A key strategic pillar is the consistent growth of its high-margin recurring revenue stream—derived from consumables, reagents, and services—which has fundamentally improved the quality and predictability of its earnings profile. The transformative 2021 acquisition of Paramit has pivoted the company’s OEM segment into the high-growth medical technology contract development and manufacturing (CDMO) market, significantly expanding its total addressable market.

Financially, Tecan has a strong historical track record of growth and profitability. The 2022-2024 period was marked by a challenging operating environment, characterized by the normalization of post-COVID demand, significant currency headwinds from a strong Swiss franc, cost inflation, and regional market weakness, particularly in China. Despite a decline in reported sales in 2024, the company demonstrated notable operational resilience, maintaining a robust adjusted EBITDA margin and strong operating cash flow, underscoring a flexible cost structure and disciplined management. The company maintains a strong balance sheet, with a net liquidity position that provides substantial flexibility for its primary capital allocation priority: strategic, accretive M&A.

Key risks include the cyclicality of customer R&D spending, a structural currency disadvantage due to its Swiss domicile, and significant customer concentration within the Partnering Business. The competitive landscape is dominated by large, well-capitalized players, necessitating a focused and efficient innovation strategy from Tecan.

The recent appointment of a new CEO with extensive experience at industry leader Thermo Fisher Scientific signals a potential new phase of growth, focused on scaling operations and enhancing commercial execution. Overall, Tecan presents as a high-quality, innovative leader in a structurally growing industry, currently navigating a period of market normalization and poised to capitalize on long-term tailwinds.

1. COMPANY OVERVIEW & BUSINESS MODEL

Core Business Segments and Revenue Streams

Tecan Group Ltd. operates through a synergistic, dual-segment business model that allows it to engage with the life sciences and diagnostics markets from two distinct but complementary angles: directly with end-users and as a strategic partner to other industry players.1 This structure enables the company to capture value across the entire product development lifecycle, from initial academic research to regulated clinical and medical applications.

  • Life Sciences Business (End-Customer): This segment focuses on the development, production, and direct sale of Tecan-branded automated workflow solutions to end-users. Customers include pharmaceutical and biotechnology companies, university research departments, and diagnostic laboratories.2 The revenue streams are generated from the initial sale of laboratory instruments, software, and subsequent recurring sales of proprietary consumables (e.g., pipette tips), reagents, spare parts, and service contracts.1 For the fiscal year (FY) 2024, the Life Sciences Business generated sales of CHF 397.0 million.3 In the first half (H1) of 2025, the segment reported sales of CHF 185.7 million, marking a return to growth with a 1.6% increase in local currencies, indicating a potential recovery from the challenging prior year.5
  • Partnering Business (OEM): This segment functions as an Original Equipment Manufacturer (OEM), developing and manufacturing instruments, modules, and components that are subsequently sold by partner companies under their own brand names.2 This business leverages Tecan’s core competencies in automation and engineering to provide solutions for leading in-vitro diagnostics (IVD), life sciences, and medical technology companies. Following the acquisition of Paramit, this segment has significantly expanded its capabilities into a full-service contract development and manufacturing organization (CDMO) for complex medical devices.7 FY 2024 revenue for the Partnering Business was CHF 537.3 million.3 H1 2025 revenue was CHF 253.8 million, reflecting an anticipated decline of 7.1% in local currencies due to customer inventory adjustments and challenging market conditions.5

The interplay between these two segments creates a robust business ecosystem. The Partnering Business provides deep insights into the long-term technology roadmaps of major diagnostics and MedTech companies, which in turn informs the R&D pipeline for the Life Sciences Business. Conversely, new technologies and modules developed for Tecan’s branded products can be offered as OEM components, accelerating market adoption and providing an efficient return on R&D investment.

Key Products and Services

Tecan offers a comprehensive portfolio of instruments, consumables, and services tailored to the needs of its diverse customer base.

  • Life Sciences Business: The product portfolio is centered around laboratory automation. Flagship instrument platforms include the Fluent® and Freedom EVO® series of liquid handling workstations, which automate complex laboratory workflows.8 In 2025, Tecan launched the
    Veya™ multi-omics liquid handling workstation, designed to “democratize” automation with a more intuitive user interface for a broader range of labs.6 The portfolio also includes a range of microplate readers (e.g.,
    Spark® series), washers, and specialized instruments. These hardware offerings are supported by a growing suite of software, such as the FlowPilot™ scheduling software, and a wide array of functional consumables and reagents, including solutions for Next-Generation Sequencing (NGS) sample preparation.1
  • Partnering Business: The offerings are structured to provide scalable solutions, from individual components to full-scale contract manufacturing. This includes the Cavro® line of market-leading OEM components like precision pumps and robotic arms; Synergence™, which offers the development of customized OEM systems; and Paramit®, which provides end-to-end contract design and manufacturing services for complex medical devices and life science instruments.1

Geographic Revenue Distribution and Market Exposure

Tecan is a global company with manufacturing and R&D sites in Europe, North America, and Asia, and a sales and service network covering over 70 countries.10 Despite its global reach, revenue is concentrated in developed markets.

The geographic breakdown of revenue for FY 2024 underscores this concentration, with the Americas accounting for 56.81% of sales, Europe for 29.37%, and Asia for 12.72%.12 This highlights a significant exposure to the spending cycles of the North American and European biopharma and diagnostics industries. To diversify its geographic exposure, Tecan is actively expanding its presence in high-growth regions. A notable recent initiative was the 2024 acquisition of a long-standing distributor in South Korea to establish a direct sales and service office, enabling the company to better serve this growing market.4

Business Model Characteristics

Tecan’s business model is characterized by its focus on creating long-term value through high customer stickiness and a growing base of predictable, recurring revenue.

  • Recurring vs. One-Time Revenue: A central element of Tecan’s strategy is to increase its proportion of recurring revenues. This “razor/razor-blade” model, where the initial instrument sale (the “razor”) drives a long-term stream of proprietary consumables and service contracts (the “blades”), enhances revenue stability and margin profile. The company has executed this strategy successfully; in the Life Sciences Business, the share of recurring revenues from services, consumables, and reagents has steadily increased from approximately 42% in 2017 to 52.8% in 2023, 57.6% in 2024, and reached 62.1% in H1 2025.6 This shift fundamentally improves the quality of earnings and is a key driver for the company’s valuation.
  • Capital Intensity and Customer Stickiness: The business model is described as “CAPEX-light,” focusing on intellectual property, assembly, and systems integration rather than heavy industrial manufacturing.14 This results in strong free cash flow generation. Customer stickiness is exceptionally high across both segments. For the Life Sciences Business, once an instrument is integrated into a lab’s validated workflow, the cost and effort required to switch to a competitor are prohibitive. For the Partnering Business, the deep integration into a partner’s product design, manufacturing, and regulatory filings creates a powerful lock-in effect and a long-term, symbiotic relationship.

2. INDUSTRY DYNAMICS & MARKET POSITION

Laboratory Automation and Life Sciences Equipment Market

Tecan operates within the broader life sciences tools industry, with specific exposure to the laboratory automation and in-vitro diagnostics (IVD) markets. These markets are supported by strong, long-term secular growth drivers.

  • Market Size and Growth:
  • Laboratory Automation: The global market was valued at approximately USD 6.5-7.8 billion in 2024/2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% to 9.4% through 2030-2035.15 This reflects steady, mature growth driven by the continuous need for efficiency and reproducibility in labs.
  • Life Science Tools: This is a significantly larger market, with estimates ranging from USD 57 billion to USD 167 billion in 2024. It is forecast to grow at a more rapid CAGR of 5.8% to 13.9%, fueled by the high pace of innovation in biotechnology and pharmaceutical research.18
  • In-Vitro Diagnostics (IVD): This key end-market for Tecan’s Partnering Business was valued at USD 74-108 billion in 2024 and is expected to grow at a CAGR of 5.6% to 7.6%.21

The divergence in these growth rates is significant. While the core automation market grows at a solid single-digit pace, the underlying scientific fields it serves, such as biotechnology, are expanding at double-digit rates.24 This implies that the intensity of automation adoption within these high-growth areas is increasing, providing a powerful tailwind for companies like Tecan that are strategically focused on these applications.

Key Industry Drivers

Several powerful, long-term trends underpin the growth of Tecan’s end markets.

  • Pharmaceutical and Biotechnology R&D Spending: The primary driver for the industry is the level of investment in research and development by pharmaceutical and biotech companies. The top 20 global pharma companies alone spent over USD 145 billion on R&D in 2022-23, a figure that continues to trend upwards.26 These expenditures directly fund the procurement of advanced laboratory tools and automation systems.
  • Growth of the Biotechnology Sector: The biotechnology industry is in a period of rapid expansion, fueled by breakthroughs in areas like CRISPR gene editing, mRNA vaccines, and cell and gene therapies.28 These complex, data-intensive applications are heavily reliant on high-precision automation to ensure scalability and reproducibility.
  • Demand for Automation: The broader trend of replacing manual laboratory processes with automated solutions is driven by multiple factors: the need for higher throughput in areas like drug screening, the demand for greater data accuracy and reproducibility to meet regulatory standards, and the challenge of addressing shortages of skilled laboratory personnel.15

Market Structure and Fragmentation

The laboratory automation market is moderately consolidated. The top five players, which include large diversified companies like Thermo Fisher Scientific and Danaher alongside specialized automation leaders like Tecan and Hamilton, are estimated to control between 45% and 60% of the market.32 The competitive landscape is tiered, with these established leaders at the top, followed by a number of smaller, niche players and disruptive new entrants focused on specific applications or business models.32

Regulatory Environment

The life sciences and diagnostics industries are subject to stringent regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and European authorities. A landmark development is the FDA’s Final Rule on Laboratory Developed Tests (LDTs), issued in May 2024.34 This rule will gradually phase out the FDA’s long-standing policy of enforcement discretion for LDTs, requiring them to meet the same regulatory standards as commercial IVD products over a four-year period.35

This regulatory shift is poised to significantly increase the compliance burden and cost for clinical laboratories that develop their own tests. Consequently, it creates a powerful incentive for these labs to outsource the development and manufacturing of their diagnostic platforms to established, FDA-compliant partners. This trend represents a potential structural tailwind for Tecan’s Partnering Business, which has deep expertise in navigating these complex regulatory environments.

Technology Trends

The industry is being reshaped by rapid technological advancements, particularly in digitalization and connectivity.

  • Digitalization and AI: The integration of artificial intelligence (AI) and machine learning is a dominant trend, enabling smarter workflows, advanced data analytics, and predictive maintenance of instruments.15 The industry is moving beyond selling standalone instruments toward providing integrated “platforms” or “ecosystems” of hardware, software, and consumables. Tecan is actively pursuing this strategy with its digital suite of products, including Introspect for remote fleet management and an open, modular software architecture to foster an interconnected lab environment.9
  • Modularity and Accessibility: There is a growing demand for more flexible, modular automation systems that can be easily configured, scaled, and operated by non-specialists.37 Tecan’s recent product launches, such as the Veya™ workstation, are aimed at “democratizing” automation by simplifying the user experience and lowering the barrier to adoption for a wider range of laboratories.9

3. COMPETITIVE LANDSCAPE

Major Competitors and Market Position

Tecan operates in a competitive environment populated by some of the largest and most sophisticated companies in the life sciences industry. The landscape includes:

  • Large Diversified Conglomerates: Companies like Thermo Fisher Scientific and Danaher Corporation (through its subsidiaries Beckman Coulter and Molecular Devices) are formidable competitors with vast product portfolios, extensive global reach, and significant financial resources.32
  • Specialized Automation Leaders: This group includes Tecan itself and its primary direct competitor, the privately-held Hamilton Company. Both are highly regarded for their Swiss-engineered, high-precision liquid handling platforms.33
  • Other Life Science Tool Providers: Companies such as Agilent Technologies, Revvity (formerly PerkinElmer), and Eppendorf also compete in various segments of the lab automation and consumables market.40

Tecan is firmly established as a top-tier player, particularly in the automated liquid handling and OEM solutions markets. In the global automated liquid handling systems market, the top five players, including Tecan, command a share of 60-65%.42 The company is generally perceived as a premium brand, known for the quality, reliability, and advanced capabilities of its hardware.43

A unique aspect of Tecan’s competitive positioning is its “frenemy” dynamic within the Partnering Business. The company develops and supplies critical components and entire systems for major diagnostics companies—including Thermo Fisher Scientific, Siemens Healthineers, and Sysmex—that are also its competitors in the end-user market.9 This situation underscores Tecan’s technological leadership and trusted status in its core areas of expertise, as even its largest rivals find it more advantageous to partner with Tecan than to develop certain technologies in-house.

Competitive Advantages and Differentiation Factors

Tecan has cultivated several durable competitive advantages that form a protective moat around its business.

  • Synergistic Business Model and OEM Moat: The dual-segment model is a core strategic advantage. The Partnering Business, in particular, creates an exceptionally strong moat. By deeply embedding its technology and manufacturing processes into the product development cycles of its OEM partners, Tecan establishes long-term, high-switching-cost relationships. For a partner to switch providers would require a complete redesign of their product, extensive re-validation, and new regulatory submissions—a prohibitively expensive and time-consuming endeavor.45
  • Brand Reputation and Installed Base: With over four decades of experience, the Tecan brand is synonymous with Swiss engineering, precision, and reliability.47 A large global installed base of instruments creates a recurring revenue stream from tied consumables and services, reinforcing customer loyalty.
  • Technological Leadership in Niche Areas: Tecan is a leader in high-precision liquid handling, robotics, and detection technologies. Its strategy focuses on innovation in modular and flexible platforms, such as the Cavro® Magni Flex and the Fluent® automation workstation, which allow for rapid customization and a faster time-to-market for its customers.14
  • Integrated Solutions and Regulatory Expertise: Tecan is increasingly moving beyond selling instruments to providing complete, validated workflow solutions that include software, reagents, and consumables. The acquisition of Paramit significantly enhanced its capabilities in providing vertically integrated, regulatory-compliant manufacturing for the highly regulated medical device market.7

Barriers to Entry

The barriers to entry in the laboratory automation market are substantial, protecting incumbent players like Tecan. These include:

  • High Capital Investment and R&D Costs: Developing and commercializing sophisticated robotic systems requires significant upfront investment in R&D, engineering, and manufacturing.49
  • Deep Technical Expertise and Intellectual Property: Success requires a multidisciplinary understanding of robotics, fluid dynamics, software engineering, and biology. Established players protect their innovations with a strong portfolio of patents.2
  • Stringent Regulatory Hurdles: Navigating the complex and evolving regulatory requirements of the FDA and other global bodies is a major challenge for new entrants, especially for instruments intended for clinical or diagnostic use.23
  • Established Customer Relationships and Brand Trust: Overcoming the long-standing relationships and trust that incumbents have built with major pharmaceutical and diagnostic companies is extremely difficult.

Innovation and R&D Investment

Innovation is critical to maintaining a competitive edge. Tecan consistently invests in R&D to enhance its product portfolio. For FY 2024, the company’s gross research and development expenditure was CHF 80.95 million, which represented 7.3% of sales.51 While this is a robust level of investment relative to its own sales, it is dwarfed in absolute terms by the R&D budgets of its larger, diversified competitors.

Table 1: R&D Investment Benchmarking (FY 2024)

CompanyRevenue (USD Billions)R&D Expense (USD Billions)R&D as % of Revenue
Tecan Group$1.06$0.097.3% (Gross)
Thermo Fisher Scientific$42.88$1.403.3%
Danaher Corporation$23.88$1.586.6%
Agilent Technologies$6.83 (FY23)$0.50 (FY23)7.3%
Note: Tecan figures converted from CHF to USD for comparison. Agilent data is for FY2023 as FY2024 data was not available in the provided materials. Sources:.3

This comparison highlights a key aspect of Tecan’s competitive strategy. Unable to outspend its larger rivals, the company must focus on R&D efficiency. Its emphasis on creating modular platforms, where core hardware and software components can be leveraged across multiple products and customer applications, is a capital-efficient approach to innovation that allows it to compete effectively within its chosen niches.

4. FINANCIAL PERFORMANCE & GROWTH HISTORY

Revenue Growth Trajectory

Tecan has demonstrated a strong long-term growth trajectory, though performance in the most recent period has been impacted by market-wide headwinds. Over the past decade, the company has successfully grown its sales through a combination of organic initiatives and strategic acquisitions.

Sales grew from CHF 440.3 million in 2015 to a peak of CHF 1,144.3 million in 2022.55 This period includes a phase of extraordinary growth in 2020 and 2021, when the COVID-19 pandemic drove unprecedented demand for automation solutions and consumables related to diagnostic testing.57

The period from 2022 to 2024 has been one of normalization and market challenges. Following the pandemic-driven peak, the company faced difficult year-over-year comparisons, coupled with reduced spending from biopharma customers and weakness in China. As a result, sales declined to CHF 1,074.4 million in 2023 and further to CHF 934.3 million in 2024, a decrease of 11.5% in local currencies.3 However, management has indicated that the underlying business, excluding COVID-related effects, continued to grow through this period.59 The first half of 2025 showed signs of stabilization, with the sales decline moderating to 3.7% in local currencies and the Life Sciences segment returning to positive growth.5

Profitability Trends

Tecan has historically maintained a strong profitability profile, with adjusted EBITDA margins consistently in the high-teens to low-20s percentage range.

  • Adjusted EBITDA Margin: The margin stood at 18.9% in 2015, expanded during the high-volume years of the pandemic to a peak of 22.7% in 2021, and was 20.5% in 2023.55 In 2024, the margin compressed to
    17.6%, primarily due to the negative operating leverage from lower sales volumes.3 The company’s ability to maintain a robust margin even during a significant sales downturn highlights a flexible cost structure and the positive impact of its operational resilience program.
  • Net Profit: Adjusted net profit followed a similar trajectory, growing from CHF 164.4 million in 2023 to CHF 103.1 million in 2024.3 The decline in 2024 reflects the lower operating profit.

Working Capital Management and Cash Conversion

A key strength of Tecan’s financial profile is its consistent and efficient cash generation.

  • Operating Cash Flow: Despite the decline in profitability, operating cash flow remained strong at CHF 148.5 million in 2024, compared to CHF 160.6 million in the stronger 2023 fiscal year.3 This resilience points to effective working capital management.
  • Cash Conversion: The company’s cash conversion, measured as operating cash flow as a percentage of reported EBITDA, improved markedly to 100.0% in 2024 from 77.5% in 2023.3 This high conversion rate underscores the quality of Tecan’s earnings. This strong performance continued into H1 2025, with cash conversion exceeding 100%.5

Balance Sheet Strength and Debt Levels

Tecan maintains a conservative and exceptionally strong balance sheet, which provides significant strategic flexibility.

  • Net Liquidity: As of December 31, 2024, the company was in a net liquidity position of CHF 153.7 million, meaning its cash and cash equivalents exceeded its total financial debt.3 This position strengthened further to CHF 140.3 million by the end of H1 2025.61
  • Debt History: The company took on debt to help finance the USD 1.0 billion acquisition of Paramit in 2021, issuing a CHF 250 million bond.58 However, its strong cash generation allowed it to quickly return to a net cash position, demonstrating a disciplined approach to leverage. This robust balance sheet serves as a strategic weapon, enabling the company to fund its growth initiatives, pursue opportunistic M&A, and return capital to shareholders without financial strain.

Table 2: Key Financial Metrics Summary (2019-2024)

Metric (in CHF millions)201920202021202220232024
Total Sales636.8730.9946.61,144.31,074.4934.3
Sales Growth (LC %)8.0%18.7%29.0%21.3%-1.3%-11.5%
Adjusted EBITDA122.8¹156.5214.5229.9220.6164.4
Adjusted EBITDA Margin (%)19.3%¹21.4%22.7%20.1%20.5%17.6%
Adjusted Net Profit73.2²103.7²152.1154.4164.4103.1
Adjusted EPS (CHF)6.18²8.69²12.3512.1412.888.08
Operating Cash Flow98.8208.3169.9128.3160.6148.5
Net (Debt)/Liquidity312.4467.7(Net Debt)³41.2112.6153.7
¹Reported EBITDA used for 2019 as Adjusted EBITDA was not provided in the same format.²Reported Net Profit/EPS used for 2019-2020.³Tecan held a net debt position post-Paramit acquisition before returning to net liquidity.Sources:.3

5. GROWTH OPPORTUNITIES & STRATEGIC INITIATIVES

Tecan’s growth strategy is multifaceted, combining organic growth from innovation and market expansion with a disciplined M&A program to enter new markets and acquire new capabilities.

Organic Growth Prospects

Organic growth is centered on innovation in high-growth application areas and expanding the company’s base of recurring revenue.

  • Focus on High-Growth Applications: The company is strategically targeting segments of the life sciences market that are growing faster than the overall industry. These include genomics (particularly NGS sample preparation), proteomics, and cell and tissue analysis.14 By providing automation solutions that address key bottlenecks in these complex workflows, Tecan can capture a greater share of customer R&D budgets.
  • New Product Development: Innovation is a key driver of instrument sales. Recent product launches are designed to broaden market access and enhance capabilities. The Veya™ workstation aims to “democratize” automation by offering an intuitive, user-friendly platform for labs that may have previously found automation too complex.6 This strategy expands the total addressable market beyond traditional high-throughput screening labs. Collaborations, such as the
    Duo Digital Dispenser™ developed with HP, bring new technologies to the portfolio and address emerging needs like single-cell dispensing.6
  • Expansion of Recurring Revenues: A core organic growth driver is the continued expansion of the consumables and reagents portfolio. As the global installed base of Tecan instruments grows, so does the captive market for its proprietary, high-margin pipette tips and specialized reagent kits.66

Market and Vertical Expansion

Tecan is pursuing growth by expanding its presence in key geographic markets and entering new industry verticals.

  • Geographic Expansion: While strong in North America and Europe, the company sees significant opportunity in the Asia-Pacific region. To capitalize on this, Tecan is shifting from a distributor-led model to a direct sales presence in key countries. The 2024 establishment of a direct sales office in South Korea is a clear execution of this strategy, allowing for closer customer relationships and better market penetration.4
  • Vertical Expansion into MedTech: The 2021 acquisition of Paramit was a transformative move that provides Tecan with a robust platform for growth in the medical device CDMO market.48 This vertical expansion allows Tecan to leverage its expertise in precision engineering and manufacturing for fast-growing MedTech applications, such as components for robotic surgery and cardiovascular devices, which have different growth drivers than its traditional life sciences markets.14

Acquisition Strategy

M&A remains a central pillar of Tecan’s growth strategy, with a proven track record of successfully acquiring and integrating companies to enhance its strategic position.

  • Strategic Rationale: Acquisitions are used to enter adjacent technology areas (e.g., NuGEN for NGS reagents), add key components (e.g., Pulssar for pumps), and expand into new business models (e.g., IBL International for immunoassays).7
  • Transformative M&A: The scale of the Paramit acquisition signals an evolution in Tecan’s M&A strategy, from smaller, “tuck-in” deals to large, transformative transactions that can fundamentally reshape the company’s market position and growth trajectory.67 The company’s strong balance sheet provides the firepower to continue pursuing this strategy.14

Digital Transformation Initiatives

Tecan recognizes that the future of laboratory automation lies in connectivity and data. The company is investing in building an “open digital ecosystem” to create a new competitive moat based on software and data integration.14 This initiative includes:

  • Smart Instruments and Software: Developing intelligent software like Introspect for remote monitoring and predictive maintenance of instrument fleets.9
  • Integrated Workflow Management: Creating platforms that connect Tecan and third-party instruments, allowing labs to manage entire workflows from a single interface, thereby increasing efficiency and reducing operational friction.9

6. CAPITAL ALLOCATION STRATEGY

Tecan’s capital allocation strategy is disciplined and balanced, prioritizing investment for long-term growth while also consistently returning capital to shareholders. The primary focus of capital deployment is on strategic M&A, supported by a strong balance sheet and robust cash flow generation.14

M&A Strategy and Track Record

Mergers and acquisitions are the cornerstone of Tecan’s strategy for inorganic growth. The company has a long and successful history of acquiring and integrating companies to gain access to new technologies, expand its product portfolio, and enter adjacent markets. The USD 1.0 billion acquisition of Paramit in 2021 stands as the largest in the company’s history and demonstrates a sophisticated approach to financing transformative deals. The acquisition was funded through a combination of cash reserves, a CHF 250 million bond issuance, and a CHF 357.5 million placement of new shares.58 This multi-faceted financing strategy allowed Tecan to execute a deal of significant scale while maintaining a manageable capital structure, showcasing its capability to pursue large transactions in the future.

Dividend Policy

Tecan has a well-established policy of providing a stable and growing dividend, signaling the Board of Directors’ confidence in the company’s long-term cash-generating ability.

  • Progressive Dividend Growth: The company has consistently increased its dividend per share over the past decade. The proposed dividend for FY 2024 is CHF 3.00, held stable from the prior year despite a decline in earnings.59 This decision to maintain the dividend during a challenging year is a strong signal of management’s belief that the downturn is temporary and that the company’s long-term earnings power remains intact.
  • Conservative Payout Ratio: The dividend payout has been managed conservatively, typically around 30% of earnings in normal years, ensuring that sufficient capital is retained for reinvestment in the business.60

Table 3: Dividend History and Payout Ratio (2019-2024)

Fiscal YearDividend per Share (CHF)Adjusted EPS (CHF)Payout Ratio (%)
2024 (Proposed)3.008.0837.1%
20233.0012.8823.3%
20222.9012.1423.9%
20212.8012.3522.7%
20202.308.69²26.5%
20192.206.18²35.6%
Note: Dividend shown is for the respective fiscal year and is typically paid in the following calendar year. Payout Ratio calculated as Dividend per Share / Adjusted EPS.²Reported EPS used for 2019-2020.Sources:.3

Share Buyback Programs

Share repurchases are used opportunistically to return additional capital to shareholders. On August 12, 2025, Tecan announced a new, significant share buyback program of up to CHF 120 million, to be executed over a maximum of two years.72 This program marks a notable shift in capital return policy, coming after a period focused heavily on M&A investment and a subsequent decline in the company’s share price. The timing suggests that management sees the ability to both fund its growth ambitions and return substantial capital, and may view its shares as undervalued. The repurchased shares are intended for general business purposes, including potential future acquisitions, providing strategic flexibility.73

Capital Expenditure

Consistent with its “CAPEX-light” business model, capital expenditures are modest and primarily directed toward maintaining and expanding manufacturing capabilities—such as the facility in Penang, Malaysia—and supporting the R&D pipeline.74

7. RECENT DEVELOPMENTS & CHALLENGES (2022-2024)

The 2022-2024 period has been transformative and challenging for Tecan, marked by the integration of its largest-ever acquisition against a backdrop of significant macroeconomic and industry-specific headwinds.

Post-COVID-19 Demand Normalization

The primary challenge during this period was the normalization of demand following the unprecedented surge related to the COVID-19 pandemic. In 2020 and 2021, Tecan experienced extraordinary growth from sales of automation platforms and pipette tips used for large-scale COVID-19 testing.57 The subsequent decline in this demand created difficult year-over-year comparisons and was a major contributor to the sales decline in 2023 and 2024.3 This “hangover effect” has masked the underlying performance of the company’s core, non-COVID business lines.

Macroeconomic and Geopolitical Headwinds

Tecan’s performance was further impacted by a confluence of external pressures:

  • Supply Chain and Inflation: Like many industrial companies, Tecan faced supply chain challenges and significant cost inflation for raw materials and freight, which put pressure on gross margins.64
  • Currency Headwinds: As a company reporting in Swiss francs (CHF) with the majority of its sales in US dollars and euros, the strengthening of the CHF has been a persistent and significant headwind. This currency translation effect consistently reduces the value of reported sales and profits. For instance, in H1 2025, sales declined 5.9% in CHF but only 3.7% in local currencies, illustrating the material impact of foreign exchange movements.6
  • US Tariffs: The company’s profitability has been negatively affected by US tariffs on goods manufactured in certain regions. For 2025, the estimated gross impact is in the low-teens of millions of Swiss francs, though the company is actively implementing mitigation measures to reduce this impact.77
  • Regional Market Weakness: Performance was dampened by a slowdown in capital spending from biopharmaceutical customers globally and a general market weakness in China, which affected both direct sales and sales through OEM partners with exposure to the region.3

Strategic and Operational Responses

In response to these challenges, management has undertaken several key initiatives:

  • Operational Resilience Program: Tecan launched a comprehensive cost-reduction and operational optimization program. This is not merely a temporary cost-cutting measure but involves structural changes to enhance long-term efficiency. Key actions include the consolidation of its US footprint, with the closure of two sites in California, and the transfer of production for certain product lines to its lower-cost, state-of-the-art facility in Penang, Malaysia.3
  • Paramit Integration: A major operational focus has been the successful integration of Paramit, acquired in August 2021. This process involved aligning manufacturing systems, quality processes, and commercial teams to leverage the combined entity’s strengths in the MedTech CDMO space.48

Management Changes

The period has also seen a significant and carefully planned leadership transition.

  • CEO Transition: In July 2025, Tecan announced that Dr. Achim von Leoprechting would step down as CEO after a successful 6.5-year tenure. He is being succeeded by Monica Manotas, who joined Tecan’s Board of Directors in April 2024.82 This transition appears to be a strategic appointment rather than a reaction to recent performance. Ms. Manotas brings over two decades of senior executive experience from Thermo Fisher Scientific, the industry’s largest player. Her background suggests a focus on scaling operations and driving commercial excellence in Tecan’s next phase of growth. The transition has been managed to ensure continuity, with the outgoing CEO remaining in an advisory role and the incoming CEO already familiar with the company from her board position.
  • Divisional Leadership: In June 2024, Mukta Acharya was appointed as the new Head of the Life Sciences Business division, bringing fresh leadership to a key segment of the company.58

8. RISK FACTORS

An investment in Tecan Group is subject to a range of industry-specific, operational, and financial risks that must be carefully considered.

Industry-Specific Risks

  • Cyclicality of End-Market Spending: Tecan’s financial performance is closely tied to the capital expenditure and R&D budgets of its customers in the pharmaceutical, biotechnology, and academic sectors. These budgets can be cyclical and are influenced by factors such as the availability of government funding, the success of clinical trials, and overall economic conditions. A downturn in R&D spending, as was observed in 2024, can lead to project delays and deferred instrument purchases, directly impacting Tecan’s revenue.3
  • Technological Obsolescence: The life sciences tools industry is characterized by rapid technological innovation. The emergence of new scientific methods or competing automation technologies could render existing products obsolete. The primary technological risk is shifting from hardware precision to software and data integration. A failure to maintain a leading-edge, user-friendly, and open digital ecosystem could diminish the attractiveness of Tecan’s hardware platforms.84
  • Regulatory Environment: The company operates in a highly regulated industry. Changes in regulations, such as the EU’s In Vitro Diagnostic Regulation (IVDR) or the FDA’s new rule on Laboratory Developed Tests (LDTs), can increase compliance costs, lengthen product development timelines, and impact market access.23

Company-Specific Operational and Financial Risks

  • Customer Concentration: A significant portion of the Partnering Business revenue is derived from a limited number of large OEM customers. The loss of a key partner, a reduction in their market share, or a decision to in-source manufacturing could have a material adverse effect on Tecan’s financial results. This risk was highlighted in 2024 when reductions in OEM customer forecasts were a primary factor in the company’s revised outlook.79
  • M&A Integration Risk: Tecan’s growth strategy is heavily dependent on acquisitions. While the company has a strong track record, there is always a risk that it may fail to successfully integrate an acquired business, realize expected synergies, or retain key personnel, particularly with a large and complex acquisition like Paramit.
  • Supply Chain Vulnerability: The company relies on a global network of suppliers for specialized components. Disruptions to this supply chain due to geopolitical events, natural disasters, or trade disputes could lead to production delays and increased costs.75

Geographic and Currency Exposure Risks

  • Currency Translation Risk: As a Swiss-domiciled company reporting in Swiss francs (CHF), Tecan faces a structural currency disadvantage. With the majority of its revenues generated in US dollars and euros, a strengthening of the CHF (often seen as a “safe-haven” currency in times of global uncertainty) negatively impacts the translation of foreign sales and profits into its reporting currency. This can depress reported growth rates even when the underlying business is performing well in local currencies.6
  • Geopolitical and Market-Specific Risks: Tecan’s exposure to global markets makes it vulnerable to regional economic downturns and political instability. The market weakness in China during 2024 demonstrated this risk, as it impacted both direct sales and the sales of OEM partners with significant business in the region.3 Furthermore, the company is exposed to trade policy risks, such as the imposition of tariffs by the U.S., which directly impact profitability.77

9. VALUATION ANALYSIS

The valuation of Tecan Group reflects its position as a high-quality leader in a growing industry, balanced against recent performance challenges and its scale relative to larger peers.

Current Trading Multiples

As of August 2025, Tecan’s valuation multiples indicate a market that is pricing in a significant earnings recovery.

  • Price-to-Earnings (P/E) Ratio: The trailing twelve-month (TTM) P/E ratio stands at approximately 34-35x.1 In contrast, the forward P/E ratio, based on consensus analyst estimates for the next twelve months, is significantly lower at approximately
    22.2x.88 This substantial gap between the trailing and forward multiples implies that the market expects a strong rebound in earnings from the depressed levels of 2024. The current valuation is therefore a “show-me” story, contingent on management’s ability to deliver on these growth expectations.
  • Enterprise Value (EV) Multiples: The TTM EV/EBITDA ratio is in the range of 17.7x to 20.5x, and the TTM EV/Sales ratio is approximately 2.3-2.4x.87 These multiples are critical for comparing Tecan to its peers, as they are independent of capital structure and tax differences.

Peer Group Valuation Comparison

A comparison with key peers in the life sciences tools and diagnostics industry provides essential context for Tecan’s valuation. The peer group includes large, diversified leaders and other specialized instrument providers.

Table 4: Peer Group Valuation Multiples

CompanyMarket Cap (USD B)EV/Sales (NTM)EV/EBITDA (NTM)P/E (NTM)
Tecan Group~2.5~2.3x~17.7x~22.2x
Thermo Fisher Scientific188.2N/AN/AN/A
Danaher Corp.147.3N/AN/AN/A
Agilent TechnologiesN/AN/AN/AN/A
Mettler-Toledo27.2N/AN/AN/A
Sartorius AGN/AN/AN/AN/A
Peer Average (Select Group)N/AN/AN/A~40.1x (Trailing)
Note: NTM = Next Twelve Months. Peer data beyond what is available in the provided materials is required for a complete comparison. The peer average P/E is from a select group and may not be fully representative. Sources:.1

While a complete NTM peer comparison is limited by the provided data, the available information suggests that Tecan’s forward P/E of ~22x is not excessive in the context of an industry where high-quality companies can command significant premiums. The peer average trailing P/E of 40.1x provided by one source suggests that Tecan’s trailing multiple of ~35x is not out of line with its peers.87

Key Valuation Drivers

The primary factors that will drive Tecan’s valuation going forward are:

  1. Return to Growth: The company’s ability to achieve its mid-term target of mid-to-high single-digit organic growth in local currencies is the most critical driver.
  2. Margin Expansion: Successful execution of the operational resilience program and favorable operating leverage from volume growth should allow the adjusted EBITDA margin to expand back toward and above 20%.
  3. Quality of Earnings: The continued growth in the share of high-margin, predictable recurring revenue justifies a valuation premium over pure-play capital equipment companies.
  4. Accretive M&A: The effective deployment of capital into value-creating acquisitions will be a key determinant of long-term shareholder returns.

Valuation Discussion

Tecan’s valuation appears to be at a pivotal point. It is no longer trading at the peak multiples seen during the pandemic but has not de-rated to the level of a typical industrial hardware company. This reflects the market’s recognition of the “quality” factors inherent in its business model: a strong competitive moat through its OEM business, a robust and growing recurring revenue stream, a net cash balance sheet, and consistent free cash flow generation. The premium valuation relative to the broader market is justified by these characteristics and its exposure to the secular growth of the life sciences industry. However, this premium is contingent on a return to profitable growth. Should the company falter in its recovery or face further market headwinds, its valuation multiples could be at risk of compression.

10. MANAGEMENT QUALITY & GOVERNANCE

Leadership Team Track Record and Experience

Tecan is undergoing a well-managed leadership transition that appears strategic in nature.

  • Outgoing CEO, Dr. Achim von Leoprechting, has been with Tecan for nearly 12 years, serving as CEO for the last 6.5 years. An internal promotion from his role as Head of the Partnering Business, his tenure ensured strategic continuity and was marked by significant growth, with revenue increasing by 60% since 2018 through both organic growth and M&A.82
  • Incoming CEO, Monica Manotas, will take the helm on August 1, 2025. Her appointment is a significant strategic move. She brings over 20 years of senior executive experience from Thermo Fisher Scientific, the industry’s largest and one of its most successful players. Her deep experience in the life sciences and diagnostics sectors, combined with her familiarity with Tecan’s business from her time on the Board of Directors since April 2024, positions her well to lead the company’s next phase of growth. This appointment can be interpreted as a deliberate effort by the board to infuse “big player” DNA into Tecan, leveraging her expertise in scaling global operations and executing commercial strategy.82

Strategic Vision and Execution

Management has demonstrated a clear strategic vision and a strong track record of execution. The successful pivot toward providing complete solutions, the consistent increase in recurring revenues, and the disciplined execution of a multi-tiered M&A strategy all point to a high level of strategic capability. The proactive implementation of the operational resilience program in 2024 in response to market headwinds further showcases an agile and disciplined management team.6

Corporate Governance Practices

Tecan appears to adhere to high standards of corporate governance.

  • Board Structure: The Board of Directors is composed of members with diverse, relevant industry experience and is structured with independent committees for Audit, Compensation, and Nomination & Governance, in line with best practices.92
  • Ethics and Compliance: The company operates under a formal Code of Conduct, is a signatory to the UN Global Compact, and maintains a third-party-managed whistleblower hotline to ensure ethical conduct and transparency.93
  • Risk Management: A formal, group-wide risk management process is in place, overseen by the CFO and ultimately the Board of Directors, to systematically identify, assess, and mitigate strategic, financial, and operational risks.95

Insider Ownership and Shareholder Alignment

Shareholder alignment is strong and has been proactively enhanced recently. In 2023 and 2024, the company introduced new minimum shareholding requirements for both the Management Board and the Board of Directors.96 These policies require executives and directors to hold a significant amount of their compensation in Tecan shares, ensuring they have a vested financial interest in the long-term success of the company. This is a strong positive governance feature that aligns the interests of management directly with those of shareholders.

Communication Quality and Transparency

Tecan maintains a high standard of communication and transparency with the investment community. The company’s investor relations website provides comprehensive access to financial reports, presentations, and corporate news.72 Financial reporting is detailed, consistently breaking out performance in both Swiss francs and local currencies to provide a clear picture of underlying business trends, separate from the impact of foreign exchange volatility.

Conclusion

Tecan Group Ltd. stands as a high-quality, strategically well-positioned company within the attractive life sciences and diagnostics industry. Its synergistic dual-business model, strong competitive moat in the OEM segment, and successful shift toward a higher-margin, recurring revenue base are core strengths that have driven a history of profitable growth.

The company is currently navigating a period of market normalization following the COVID-19 pandemic, compounded by significant macroeconomic headwinds, including a strong Swiss franc and regional market weakness. However, its operational and financial performance throughout this challenging period has demonstrated remarkable resilience, characterized by strong cash flow generation and the maintenance of a robust profitability profile and a net cash balance sheet.

Future growth is expected to be driven by a clear strategy focused on innovation in high-growth applications like genomics and cell biology, geographic expansion, and a disciplined, value-accretive M&A program. The recent, well-managed CEO transition brings in a leader with extensive experience from an industry giant, signaling an ambition to accelerate growth and scale operations to the next level.

While risks related to customer concentration, R&D spending cycles, and currency exposure persist, the company’s strong market position, durable competitive advantages, and pristine balance sheet provide a solid foundation to mitigate these challenges. The current valuation reflects market expectations for a strong earnings recovery, placing the onus on the new leadership to execute on the company’s strategic initiatives and capitalize on the long-term secular growth trends in its end markets.

Works cited

  1. Tecan Group AG Stock Price Today | SIX: TECN Live – Investing.com, accessed August 24, 2025, https://www.investing.com/equities/tecan-hld-n
  2. Tecan Trading 2025 Company Profile: Stock Performance & Earnings | PitchBook, accessed August 24, 2025, https://pitchbook.com/profiles/company/62163-64
  3. Tecan reports 2024 financial results, enhancing operational resilience amid challenging conditions, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-reports-2024-financial-results-enhancing-operational-resilience-amid-challenging-conditions-63201?hsLang=en
  4. Tecan reports 2024 financial results, enhancing operational – GlobeNewswire, accessed August 24, 2025, https://www.globenewswire.com/news-release/2025/03/12/3041106/0/en/Tecan-reports-2024-financial-results-enhancing-operational-resilience-amid-challenging-conditions.html
  5. Tecan Group AG | Globenewswire, accessed August 24, 2025, https://via.ritzau.dk/pressemeddelelse/14520181/tecan-group-ag?publisherId=90446&lang=en
  6. Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-reports-solid-financial-results-for-the-first-half-of-2025-and-confirms-its-outlook-for-full-year-2025-63233?hsLang=en
  7. Tecan company history, accessed August 24, 2025, https://www.tecan.com/history
  8. Tecan Group Home – Scaling Healthcare Innovation Globally., accessed August 24, 2025, https://www.tecan.com/
  9. CONNECTING PEOPLE AND SCIENCE TO CREATE BETTER OUTCOMES. – Tecan, accessed August 24, 2025, https://www.tecan.com/doc?airp=Tecan_Annual_Report_2024_EN.pdf
  10. PR Tecan Conference Call H1 2025_EN – Via Ritzau, accessed August 24, 2025, https://via.ritzau.dk/files/90446/14512430/256724/en
  11. Tecan – Wikipedia, accessed August 24, 2025, https://en.wikipedia.org/wiki/Tecan
  12. TECAN GROUP AG (TCHBF) Revenue Breakdown – Main Composition – Moomoo, accessed August 24, 2025, https://www.moomoo.com/stock/TCHBF-US/financials-revenue
  13. Tecan records stable sales and increased operating profit margin in …, accessed August 24, 2025, https://www.tecan.com/doc?srv=ww3&t77=180314_PR_2017_Tecan_with_significant_increase_in_sales_and_profit__EN.pdf
  14. Tecan’s Capital Markets Day highlights strategic growth drivers, groundbreaking innovation and product launches, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-s-capital-markets-day-highlights-strategic-growth-drivers-groundbreaking-innovation-and-product-launches-63209?hsLang=en
  15. Global Laboratory Automation Market to Grow at ~7% CAGR Driven by AI Integration and Tech by 2030 – PharmiWeb.com, accessed August 24, 2025, https://www.pharmiweb.com/press-release/2025-08-13/global-laboratory-automation-market-to-grow-at-7-cagr-driven-by-ai-integration-and-tech-by-2030
  16. Lab Automation Market Size to Surpass USD 14.78 Bn By 2034 – Precedence Research, accessed August 24, 2025, https://www.precedenceresearch.com/lab-automation-market
  17. Lab Automation Market Size, Share, Revenue Growth 2035 – Roots Analysis, accessed August 24, 2025, https://www.rootsanalysis.com/reports/lab-automation-market.html
  18. Life Science Lab Equipment Market Growth 2025 Driven by AI, Automation & Precision Medicine Demand – Towards Healthcare, accessed August 24, 2025, https://www.towardshealthcare.com/insights/life-science-lab-equipment-market-sizing
  19. Life Science Tools Market Size, Share | Industry Report, 2030 – Grand View Research, accessed August 24, 2025, https://www.grandviewresearch.com/industry-analysis/life-science-tools-market
  20. Life Science Tools Market Size Leads 13% CAGR by 2034 – Towards Healthcare, accessed August 24, 2025, https://www.towardshealthcare.com/insights/life-science-tools-market-size
  21. In Vitro Diagnostics Market Size, Top Share And Growth By 2033 – Straits Research, accessed August 24, 2025, https://straitsresearch.com/report/in-vitro-diagnostics-market
  22. In-vitro Diagnostics [IVD] Market Size, Trends | Growth, 2032 – Fortune Business Insights, accessed August 24, 2025, https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-ivd-market-101443
  23. In Vitro Diagnostics Market Size, Share | Industry Report, 2030 – Grand View Research, accessed August 24, 2025, https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-ivd-market
  24. Biotechnology Market Size to Hit USD 5.71 Trillion by 2034 – Precedence Research, accessed August 24, 2025, https://www.precedenceresearch.com/biotechnology-market
  25. Biotechnology Market Size And Share | Industry Report, 2030 – Grand View Research, accessed August 24, 2025, https://www.grandviewresearch.com/industry-analysis/biotechnology-market
  26. www.ifpma.org, accessed August 24, 2025, https://www.ifpma.org/wp-content/uploads/2025/02/IFPMA_Always_Innovating_Facts__Figures_Report.pdf
  27. Global pharma companies’ return on R&D investment increases after record low – Deloitte, accessed August 24, 2025, https://www.deloitte.com/uk/en/about/press-room/global-pharma-companies-return-on-rd-investment-increases-after-record-low.html
  28. Life Science Tools Market Size To Hit USD 472.22 Billion By 2034 – Nova One Advisor, accessed August 24, 2025, https://www.novaoneadvisor.com/report/life-science-tools-market
  29. Biotech Boom: How Revolutionary Advancements Are Shaping Stock Market Trends, accessed August 24, 2025, https://www.investopedia.com/understanding-the-biotech-boom-11736120
  30. Understanding The Growth Of The Lab Automation Market By 2035 – PharmiWeb.com, accessed August 24, 2025, https://www.pharmiweb.com/press-release/2025-08-11/understanding-the-growth-of-the-lab-automation-market-by-2035
  31. Surge of More Than 8.1% Drives The Lab Automation Market- – World Pharma Today, accessed August 24, 2025, https://www.worldpharmatoday.com/news/surge-of-more-than-8-1-drives-the-lab-automation-market/
  32. Thermo Fisher Scientific (US) and Tecan Group (Switzerland) are Leading Players in the Lab Automation Market – MarketsandMarkets, accessed August 24, 2025, https://www.marketsandmarkets.com/ResearchInsight/lab-automation-market.asp
  33. For those who are un-aware of laboratory automation, this is not a new industry…. | Hacker News, accessed August 24, 2025, https://news.ycombinator.com/item?id=16690165
  34. Laboratory Developed Tests – FDA, accessed August 24, 2025, https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
  35. FDA’s Final Rule on Regulation of Lab-Developed Tests: A Changing Landscape, accessed August 24, 2025, https://www.americanbar.org/groups/science_technology/resources/scitech-lawyer/2025-winter/fdas-final-rule-regulation-labdeveloped-tests-changing-landscape/
  36. FDA’s proposed rule for the regulation of laboratory-developed tests – PubMed Central, accessed August 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10865810/
  37. Get a competitive edge in clinical markets with modular OEM solutions – The Blog – Tecan, accessed August 24, 2025, https://www.tecan.com/blog/cavro-magniflex-a-new-modular-oem-solution-for-clinical-diagnostics
  38. Lab Automation Market Key Players – Tecan Group Ltd, Thermo, accessed August 24, 2025, https://www.openpr.com/news/3590419/lab-automation-market-key-players-tecan-group-ltd-thermo
  39. Pros/cons of Tecan Fluent vs Hamilton STAR – Lab Automation Forums, accessed August 24, 2025, https://labautomation.io/t/pros-cons-of-tecan-fluent-vs-hamilton-star/1656
  40. Lab Automation Market Current and Future Growth Overview, Competitor Analysis, and Forecast to 2032: Tecan Group Ltd., PerkinElmer Inc., Danaher Corporation, Thermo Fisher Scientific, QIAGEN, Agilent Technologies – Digital Journal, accessed August 24, 2025, https://www.digitaljournal.com/pr/news/lab-automation-market-current-and-future-growth-overview-competitor-analysis-and-forecast-to-2032-tecan-group-ltd-perkinelmer-inc-danaher-corporation-thermo-fisher-scientific-qiagen-agilent-technologies
  41. Global Automated Liquid Handling System Companies – Mordor Intelligence, accessed August 24, 2025, https://www.mordorintelligence.com/industry-reports/automated-liquid-handling-system-market/companies
  42. Thermo Fisher Scientific Inc. (US) and Danaher (US) are Leading Players in the Liquid Handling System Market – MarketsandMarkets, accessed August 24, 2025, https://www.marketsandmarkets.com/ResearchInsight/liquid-handling-system-market.asp
  43. Automation in the lab: Hamilton, Tecan, Biomek, or other systems? : r/biotech – Reddit, accessed August 24, 2025, https://www.reddit.com/r/biotech/comments/1amntuz/automation_in_the_lab_hamilton_tecan_biomek_or/
  44. Customer success stories – Tecan Partnering Home, accessed August 24, 2025, https://partnering.tecan.com/customer-success-stories
  45. Tecan your strategic OEM partner – Total cost of ownership, accessed August 24, 2025, https://partnering.tecan.com/synergence-oem-system-development/total-cost-of-ownership
  46. Five secrets to a successful IVD OEM partnership – The Blog – Tecan, accessed August 24, 2025, https://www.tecan.com/blog/five-secrets-invitro-diagnostics-oem-partnership
  47. SCALING HEALTHCARE INNOVATION GLOBALLY – Tecan, accessed August 24, 2025, https://www.tecan.com/doc?prar=250115_Tecan_JPM_HC_Conference.pdf
  48. Tecan acquires medical device specialist Paramit, accessed August 24, 2025, https://www.tecan.com/tecan-journal/tecan-acquires-medical-device-specialist-paramit
  49. Lab Automation Market – Trends, Segmentation, Leads, Forecast to 2030 – AllTheResearch, accessed August 24, 2025, https://www.alltheresearch.com/report/1047/lab-automation-market
  50. Modular Laboratory Automation Market Size, Share Analysis & Research Report, 2030, accessed August 24, 2025, https://www.mordorintelligence.com/industry-reports/global-modular-lab-automation-market-industry
  51. 7 Research and development – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2024/financial-report-2024/notes-to-the-consolidated-financial-statements/7-research-and-development
  52. Danaher Research and Development Expenses 2010-2025 | DHR – Macrotrends, accessed August 24, 2025, https://www.macrotrends.net/stocks/charts/DHR/danaher/research-development-expenses
  53. 2024 Thermo Fisher Scientific Annual Report, accessed August 24, 2025, https://s27.q4cdn.com/797047529/files/doc_financials/2024/ar/2024-Annual-Report.pdf
  54. Annual Report – PR Newswire Services and Resources for IR …, accessed August 24, 2025, https://filecache.investorroom.com/mr5ir_danaher/911/download/Danaher%202024%20Annual%20Report.pdf
  55. Tecan with high growth in sales and net profit in fiscal year 2015, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-with-high-growth-in-sales-and-net-profit-in-fiscal-year-2015-1998
  56. 2022 at a glance – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2022/investor-relations/2022-at-a-glance
  57. Tecan reports significant growth in sales and profits in 2020 based on extraordinary demand for COVID-19 related products, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-reports-significant-growth-in-sales-and-profits-in-2020-based-on-extraordinary-demand-for-covid-19-related-products-1935
  58. News Archive – Tecan, accessed August 24, 2025, https://www.tecan.com/news-archive
  59. Tecan reports solid underlying sales growth and an increase in …, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-reports-solid-underlying-sales-growth-and-an-increase-in-profitability-and-net-profit-for-full-year-2023-63091
  60. Five-year consolidated data – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2023/financial-report-2023/five-year-consolidated-data
  61. CONNECTING PEOPLE AND SCIENCE TO CREATE BETTER …, accessed August 24, 2025, https://www.tecan.com/doc?airp=Tecan_Interim_Report_2025_EN.pdf&hsLang=en
  62. CONNECTING PEOPLE AND SCIENCE TO CREATE BETTER OUTCOMES. – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/fileadmin/interimreport_2025/250811_Tecan_HJB_2025.pdf
  63. Press Release, accessed August 24, 2025, https://ml-eu.globenewswire.com/Resource/Download/2c886a99-721a-4835-887b-b549f3727b35
  64. Tecan Interim Report 2022, accessed August 24, 2025, https://www.tecan.com/doc?airp=Tecan_Interim_Report_2022_EN.pdf
  65. Markets and strategy – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2023/investor-relations/markets-and-strategy
  66. Tecan Group AG (TCHBF) Q2 2025 Earnings Call Transcript – Seeking Alpha, accessed August 24, 2025, https://seekingalpha.com/article/4812534-tecan-group-ag-tchbf-q2-2025-earnings-call-transcript
  67. Tecan successfully completes the acquisition of Paramit, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-successfully-completes-the-acquisition-of-paramit-2307
  68. Liquid Handling Systems Market Size, Share and Forecast, 2018-2032F – Markets and Data, accessed August 24, 2025, https://www.marketsandata.com/industry-reports/liquid-handling-systems
  69. HALF YEAR RESULTS 2025 – Public now, accessed August 24, 2025, https://docs.publicnow.com/viewDoc.aspx?filename=63275\EXT\61A6533F13817CC64CD8FE79ED5A81362A590318_F60038C57779794C507FA5A0E8A9E6B073001C38.PDF
  70. Tecan successfully completes the placement of 650,000 new shares, thereby securing funding to partly refinance the acquisition of Paramit Corporation, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-successfully-completes-the-placement-of-650-000-new-shares-thereby-securing-funding-to-partly-refinance-the-acquisition-of-paramit-corporation-39187
  71. Tecan Group AG ( TECN.SW) Dividends – Digrin, accessed August 24, 2025, https://www.digrin.com/stocks/detail/TECN.SW/
  72. Tecan Investor Overview, accessed August 24, 2025, https://www.tecan.com/investor-overview
  73. SBP – Download List – Tecan, accessed August 24, 2025, https://www.tecan.com/sbp
  74. Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025 – GlobeNewswire, accessed August 24, 2025, https://www.globenewswire.com/news-release/2025/08/12/3131392/0/en/Tecan-reports-solid-financial-results-for-the-first-half-of-2025-and-confirms-its-outlook-for-full-year-2025.html
  75. Tecan Journal, accessed August 24, 2025, https://www.tecan.com/doc?t77=Tecan_Journal_2021-01.pdf
  76. Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025, accessed August 24, 2025, https://ml-eu.globenewswire.com/Resource/Download/5f2f1b2c-047d-4177-a016-8f6f819b99ed
  77. 2025 TARIFF SURGE. – Tecan, accessed August 24, 2025, https://www.tecan.com/doc/2025-tariff-surge-what-it-means-for-medtech-life-sciences-and-diagnostics-infographic-pdf
  78. Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025, accessed August 24, 2025, https://www.tecan.com/corporate-news/q1-2025-qualitative-update-tecan-reports-performance-in-line-with-expectations-and-confirms-outlook-for-full-year-2025-63239
  79. SCALING HEALTHCARE INNOVATION GLOBALLY – Tecan, accessed August 24, 2025, https://www.tecan.com/doc?prar=241022_Tecan_CMD_2024_presentation.pdf&hsLang=en
  80. Tecan meets revised sales outlook for fiscal year 2024, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-meets-revised-sales-outlook-for-fiscal-year-2024-63205?hsLang=en
  81. Compensation Report – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2022/corporate-governance/compensation-report
  82. Tecan announces CEO transition as part of succession planning, accessed August 24, 2025, https://www.tecan.com/corporate-news/tecan-announces-ceo-transition-as-part-of-succession-planning-63259?hsLang=en
  83. Tecan announces CEO transition as part of succession planning – GlobeNewswire, accessed August 24, 2025, https://www.globenewswire.com/news-release/2025/07/10/3112980/0/en/Tecan-announces-CEO-transition-as-part-of-succession-planning.html
  84. TECN – Tariffs And Disruptions Will Crush Margins While Cuts Will Help, accessed August 24, 2025, https://simplywall.st/community/narratives/ch/pharmaceuticals-biotech/vtx-tecn/tecan-group-shares/ycyktkk3-tariffs-and-disruptions-will-crush-margins-while-cuts-will-help-6545
  85. TMS Directive Responsible Sourcing Policy – Tecan, accessed August 24, 2025, https://www.tecan.com/doc?irsp=Tecan_Responsible_Sourcing_Policy_EN.pdf&sdr=Code_of_conduct
  86. Tecan shares surge 12% on sales beat, strong orders despite tariff hit – Investing.com, accessed August 24, 2025, https://www.investing.com/news/earnings/tecan-shares-surge-12-on-sales-beat-strong-orders-despite-tariff-hit-4184307
  87. Tecan Group (SWX:TECN) Stock Valuation, Peer Comparison & Price Targets, accessed August 24, 2025, https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-tecn/tecan-group-shares/valuation
  88. Tecan Group AG (LON:0QLN) Statistics & Valuation Metrics – Stock Analysis, accessed August 24, 2025, https://stockanalysis.com/quote/lon/0QLN/statistics/
  89. Thermo Fisher Scientific Research and Development Expenses 2010-2025 | TMO, accessed August 24, 2025, https://www.macrotrends.net/stocks/charts/TMO/thermo-fisher-scientific/research-development-expenses
  90. Danaher Corporation (DHR) Stock Price, Market Cap, Segmented Revenue & Earnings – Datainsightsmarket.com, accessed August 24, 2025, https://www.datainsightsmarket.com/companies/DHR
  91. Tecan reports consolidated first quarter sales of CHF 69 – Via Ritzau, accessed August 24, 2025, https://via.ritzau.dk/files/90446/14495554/250322/en
  92. Board of Directors – Tecan, accessed August 24, 2025, https://www.tecan.com/board-of-directors
  93. Governance – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2023/investor-relations/sustainability/governance
  94. Tecan Corporate Policies, accessed August 24, 2025, https://www.tecan.com/tecan-corporate-policies
  95. 12 Group risk management – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2024/financial-report-2024/notes-to-the-financial-statements-of-tecan-group-ltd/12-group-risk-management
  96. Compensation Report Part 2 – Tecan Annual Report, accessed August 24, 2025, https://www.tecanannualreport.com/annual-report-2024/corporate-governance/compensation-report-part-1/compensation-report-part-2